Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands |
Total |
2019 Sales Agreement [Member] |
2022 Sales Agreement [Member] |
Follow On Public Offering |
At The Market Offerings |
At The Market Offerings
2019 Sales Agreement [Member]
|
At The Market Offerings
2022 Sales Agreement [Member]
|
Regeneron Pharmaceuticals Inc. [Member] |
Follow-on Offering [Member] |
Follow-on Offering [Member]
Follow On Public Offering
|
Follow-on Offering [Member]
At The Market Offerings
|
Follow-on Offering [Member]
At The Market Offerings
2019 Sales Agreement [Member]
|
Follow-on Offering [Member]
At The Market Offerings
2022 Sales Agreement [Member]
|
Follow-on Offering [Member]
Regeneron Pharmaceuticals Inc. [Member]
|
Additional Paid-In Capital |
Additional Paid-In Capital
Follow On Public Offering
|
Additional Paid-In Capital
At The Market Offerings
|
Additional Paid-In Capital
At The Market Offerings
2019 Sales Agreement [Member]
|
Additional Paid-In Capital
At The Market Offerings
2022 Sales Agreement [Member]
|
Additional Paid-In Capital
Regeneron Pharmaceuticals Inc. [Member]
|
Accumulated Other Comprehensive Income |
Retained Earnings |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Beginning balance at Dec. 31, 2019 | $ 269,881 | $ 5 | $ 570,493 | $ 261 | $ (300,878) | |||||||||||||||||
Beginning balance, shares at Dec. 31, 2019 | 50,198,044 | |||||||||||||||||||||
Issuance of common stock | $ 296,607 | $ 49,461 | $ 12,580 | $ 2 | $ 296,605 | $ 49,461 | $ 12,580 | |||||||||||||||
Issuance of common stock, shares | 2,270,161 | 11,815,069 | 2,270,161 | 925,218 | ||||||||||||||||||
Exercise of stock options | $ 11,574 | 11,574 | ||||||||||||||||||||
Exercise of stock options, shares | 840,824 | |||||||||||||||||||||
Vesting of restricted stock units, shares | 82,829 | |||||||||||||||||||||
Issuance of shares under employee stock purchase plan | $ 1,557 | 1,557 | ||||||||||||||||||||
Issuance of shares under employee stock purchase plan, shares | 101,911 | |||||||||||||||||||||
Equity-based compensation | $ 19,903 | 19,903 | ||||||||||||||||||||
Other comprehensive income - unrealized gain (loss) on marketable securities | (260) | (260) | ||||||||||||||||||||
Net loss | (134,231) | |||||||||||||||||||||
Ending balance at Dec. 31, 2020 | 527,072 | $ 7 | 962,173 | 1 | (435,109) | |||||||||||||||||
Ending balance, shares at Dec. 31, 2020 | 66,234,056 | |||||||||||||||||||||
Issuance of common stock | 648,315 | $ 45,255 | 648,315 | $ 45,255 | ||||||||||||||||||
Issuance of common stock, shares | 641,709 | 4,758,620 | 641,709 | |||||||||||||||||||
Exercise of stock options | $ 41,094 | 41,094 | ||||||||||||||||||||
Exercise of stock options, shares | 2,700,886 | |||||||||||||||||||||
Vesting of restricted stock units, shares | 119,715 | |||||||||||||||||||||
Issuance of shares under employee stock purchase plan | $ 2,024 | 2,024 | ||||||||||||||||||||
Issuance of shares under employee stock purchase plan, shares | 30,897 | |||||||||||||||||||||
Equity-based compensation | $ 47,009 | 47,009 | ||||||||||||||||||||
Other comprehensive income - unrealized gain (loss) on marketable securities | (2,126) | (2,126) | ||||||||||||||||||||
Other comprehensive loss - equity method investment | (507) | |||||||||||||||||||||
Net loss | (267,892) | |||||||||||||||||||||
Ending balance at Dec. 31, 2021 | $ 1,040,244 | $ 7 | 1,745,870 | (2,632) | (703,001) | |||||||||||||||||
Ending balance, shares at Dec. 31, 2021 | 74,485,883 | 74,485,883 | ||||||||||||||||||||
Issuance of common stock | $ 337,892 | $ 38,886 | $ 189,011 | $ 1 | $ 1 | $ 337,891 | $ 38,885 | $ 189,011 | ||||||||||||||
Issuance of common stock, shares | 3,395,339 | 579,788 | 7,532,751 | 3,395,339 | ||||||||||||||||||
Exercise of stock options | $ 14,517 | 14,517 | ||||||||||||||||||||
Exercise of stock options, shares | 883,954 | 883,954 | ||||||||||||||||||||
Vesting of restricted stock units | $ 147,674 | |||||||||||||||||||||
Issuance of shares under employee stock purchase plan | $ 2,649 | 77,618 | 2,649 | |||||||||||||||||||
Equity-based compensation | 91,400 | |||||||||||||||||||||
Other comprehensive income - unrealized gain (loss) on marketable securities | (1,637) | (1,637) | ||||||||||||||||||||
Other comprehensive loss - equity method investment | (3,192) | (3,192) | ||||||||||||||||||||
Net loss | (474,186) | |||||||||||||||||||||
Ending balance at Dec. 31, 2022 | $ 1,235,584 | $ 9 | $ 2,420,223 | $ (7,461) | $ (1,177,187) | |||||||||||||||||
Ending balance, shares at Dec. 31, 2022 | 87,103,007 | 87,103,007 |